Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705292 | 1.00 | MEP1B (0.57) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL14486524 | 0.85 | DAO (0.54) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL10919616 | 0.82 | CETP (0.43) | MEP1BDAOCETPPPARGPPARA | |
| SCHEMBL1776057 | 0.81 | MEP1B (0.54) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL297093 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL1776056 | 0.81 | MEP1B (0.54) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL10913301 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL2539937 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL29793524 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4DRD1MPO | |
| SCHEMBL1908557 | 0.81 | MEP1B (0.50) | MEP1BDAOMRGPRX4DRD1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| CN-114585603-B | Prostaglandin EP4Receptor antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-1318803-A1 | FATTY ACID SYNTHASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002092550-A1 | THYROID HORMONE RECEPTOR ANTAGONISTS FOR CARDIAC AND METABOLIC DISORDERS II | KARO BIO AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002009688-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| US-4596880-A | Pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| EP-0006978-B1 | BENZYL ESTERS WITH FLUORINATED ETHER AND/OR THIOETHER GROUPS, THEIR PREPARATIONS AND THEIR USE AS INSECTICIDES; INTERMEDIATE PRODUCTS AND THEIR PREPARATIONS | BAYER AG (DE) | 1986-01-29 | — | — | EP | disclosed |
| EP-0041131-B1 | PREPARATION OF FLUORO-SUBSTITUTED BENZODIOXOLES AND BENZODIOXANES | BAYER AG (DE) | 1984-06-13 | — | — | EP | disclosed |
| US-4438275-A | 2,2-DIFLUORO-BENZODIOXOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
| US-4310540-A | PYRETHROID-LIKE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |
| EP-0041131-A2 | Preparation of fluoro-substituted benzodioxoles and benzodioxanes | BAYER AG (DE) | 1981-12-09 | — | — | EP | disclosed |
| EP-0006978-A2 | Benzyl esters with fluorinated ether and/or thioether groups, their preparations and their use as insecticides; intermediate products and their preparations | BAYER AG (DE) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | MEP1B 857/4885DAO 4526/4885MRGPRX4 25/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | MEP1B 1266/4885DAO 4312/4885MRGPRX4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.